Comparative Pharmacology
Head-to-head clinical analysis: IBUPROHM versus RELAFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROHM versus RELAFEN.
IBUPROHM vs RELAFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Nabumetone is a nonacidic nonsteroidal anti-inflammatory drug (NSAID) that is a prodrug, rapidly metabolized to the active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which inhibits cyclooxygenase (COX) and thereby prostaglandin synthesis.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
1000 mg orally once daily, or 500 mg twice daily. Maximum dose 2000 mg/day.
None Documented
None Documented
2-4 hours in adults; prolonged to 1.5-2.5 hours in neonates? Actually: terminal half-life ~2-4 h in adults, up to 12 h in overdose; context: requires frequent dosing.
Terminal elimination half-life approximately 24 hours (range 20-30 hours), allowing once-daily dosing.
Renal: 90% as metabolites (mostly glucuronide conjugates) and unchanged drug (1%); biliary/fecal: <5%.
Primarily renal (90% as metabolites, ~5% unchanged); biliary/fecal minor (<5%).
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)